Healthcare associated infections in COVID-19 patients

COVID-19 patients suffering from severe forms of the disease are at risk of developing bacterial healthcare-associated infections, such as ventilator-associated pneumonia caused by multidrug resistant pathogens. TP-122 bacteriophage cocktail may be an alternative for such patients, because it consists of a biological therapeutic developed for the treatment of pneumonia caused by Pseudomonas aeruginosa, as an add-on therapy to the standard of care. This product developed by TechnoPhage may be used in compassionate use cases, thus helping the most fragile COVID-19 patients to overcome this additional healthcare-associated infection.